FDA Updates Guidance For Written IRB Policies

The regulatory landscape for human subject research is shifting toward greater harmony and transparency. With the recent updates to the Institutional Review Board (IRB) Written Procedures, institutions are now working to align with the 21st Century Cures Act's push for streamlined operations. This evolution moves beyond simple compliance, urging IRBs to integrate broader institutional policies into a cohesive oversight strategy. Understanding these updates is vital for maintaining the integrity of clinical trials. The latest guidance emphasizes the shift toward digital accessibility, suggesting that clear, online procedural documentation is no longer just a convenience but a cornerstone of investigator compliance. By exploring the various refinements listed here, research professionals can better evaluate their current board’s effectiveness and ensure that record-keeping, conflict-of-interest disclosures, and review processes meet contemporary expectations.